Search

1 article for “Donanemab”

• Published Subscription Original Research 9 Dec 2025

  Kisunla (Donanemab): A Novel Breakthrough Illuminating a Path to Better Alzheimer’s Outcomes

  By Muchukota Sushma, Alena Reji Thomas, Jayashree S, Priya Singha, Payal Baral, Isbha Stephen, Shobha R. R. Hiremath

  Abstract: Background: Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and loss of independence. Despite decades of extensive research, disease-modifying treatments have been limited in success. Recent therapeutic advancements have led to the development of monoclonal antibodies targeting amyloid-beta (Aβ) plaques, particularly the pyroglutamate-modified variant, a key pathological hallmark of AD. Objectives: This review aims to explore the therapeutic potential of Donanemab (Kisunla), a novel …

  Published in Research and Reviews: A Journal of Neuroscience · Vol. 15, Issue 3, 2025 · pp. 37–45 Read article →